September 24 – 26 | Boston, MA
2nd Annual Edition
Pre-Launch Passes to DTx East 2019 are now available!
Full details and launch prices will appear here in May 2019
Confirmed
Partners 2019
Partners
DTx in 60 seconds
Key Numbers of DTx
200+
Attendees
Join over 200 senior decision-makers from DTx companies, pharma, investors, payers and HCP’s.
40+
Expert Speakers
Hear from the pioneers and most exciting newcomers as they present the latest clinical updates and discuss the critical opportunities.
19
Hours of Networking
Meet with exec’s and directors from the leading companies and future players through a multitude of networking opportunities.
“The focus of the event is perfect. There is a real sense of community, with everyone pulling in the same direction and I leave with crucial new connections”
Chris Lento, VP, Commercial Operations, Pear Therapeutics
Is DTx East For You?
DTx East has been constructed by the pioneers of the industry to serve as the dedicated meeting point for those pushing the boundaries, as well as those seeking to understand the fundamentals of the field.
As this industry grows at a giddy pace, the need for key people to meet has never been greater. The DTx West event took place in February where 120 decision – makers gathered for two days of learning, discovery and collaboration.
The East Coast event builds on the success of the West Coast meeting, moving the conversation forward and facilitating the connections and conversations we all need to have.
As an attendee you will have access to the latest information, often not published elsewhere. The presentations, panels, workshops and networking discussions are transparent and frank. (Our members tell us this series is the most open they have ever attended).
Hosted at a hand-picked venue, this exclusive event provides the perfect environment for networking. If you work in the DTx sector then this is the must-attend event in the calendar.
Take a look at the agenda and speaker faculty and you will see what you will learn and why the leaders in this sector are coming together at this meeting.
2019 Confirmed Speakers
Elli Kaplan is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including at the White House, the State and Treasury Departments, and the United Nations Development Program. Elli has also held positions with AIG, Goldman Sachs and multiple startups. She has won SXSW’s best new startup and DEMO God awards, the J&J World Without Disease Challenge, and presented at TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the New York Times. Elli has an M.B.A. from Harvard Business School.
Zack Lynch is a Managing Partner and co-founder of JAZZ Venture Partners, a San Francisco-based early stage venture capital firm focused on investing in human performance technology. He is an entrepreneur and futurist who brings a rich understanding of the forces driving the convergence of digital technologies and neuroscience and how new products and services are emerging to unlock human potential across health, wellness, learning, training, sports, enterprise and entertainment. He is the author of the best selling book The Neuro Revolution: How Brain Science Is Changing our World (St. Martin’s Press) which takes a 50 year view on how neuroscience will transform human society. Zack loves to snow board and spend time with his wife and kids.
Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.
Pavan Choksi is an Investment Associate at Arkitekt Ventures, an early stage healthcare venture fund based in New York City that specializes in investments in novel models of healthcare delivery including digital therapeutics and applications of frontier technology such as artificial intelligence, augmented reality, genomics, and brain machine interfaces to medicine.
Prior to Arkitekt, he was the first employee and Vice President of Corporate Development for Rx.Health, a venture-backed Mount Sinai Health System spin-off commercializing a novel Digital Medicine prescription and delivery platform. As an active member of the digital health ecosystem, he serves as Strategic Advisor to the Digital Therapeutics Alliance and NODE Health.
Passionate about building great products with great user experience! I’m also passionate about Digital Health and value-driven healthcare.
I'm lucky spending all my time bringing this world together as the CEO of DarioHealth Corp. (NASDAQ: DRIO) a leading global digital therapeutics company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by accumulated data, high-quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way.
Already the highest rated diabetes solution by more than tens of thousands of consumers who love the user-centered approach, DarioHealth is rapidly moving into new chronic conditions and geographic markets.
Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow's evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past ``40 under 40`` who started her career as a nurse and has worked in healthcare, education and technologies companies.
Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.
Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.
Timothy Aungst, PharmD is an Associate Professor of Pharmacy Practice at MCPHS University, Worcester, MA. He graduated from Wilkes University Nesbitt School of Pharmacy, Wilkes-Barre, PA, in 2011. Afterwards, he pursued a PGY-1 Pharmacy Practice Residency at St. Luke's University Hospital, Bethlehem, PA, with an emphasis on Internal Medicine, Cardiology, and Geriatric Care. He then completed a fellowship program focused on geriatic care, Medicare/Medicaid and drug management, and academia. While completing his post-grad training, he started writing for multiple companies on mHealth and Digital Health, with a focus on mobile apps. Since then, he has conducted research on digital health technologies in the pharmacy space and published in multiple peer review journals and spoken at multiple venues on the topic. He hopes to inspire the pharmacy profession to further integrate digital health into patient care and raise awareness on the future possibilities posed in the coming decades.
Yvonne Yu-Feng Chan, MD, PhD, FACEP is the Director of the Center for Digital Health at the Icahn Institute of Mount Sinai. She is a national leader in digital medicine research and a board-certified Emergency physician. The mission of her Digital Health Center is to drive large-scale participation of patients in biomedical research and clinical care, by leveraging the latest digital technology and advanced analytic techniques to uncover novel insights and actionable results.
Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.
Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.
André is an experienced startup executive, business and sales manager, leader, and strategist. He is an expert in inside and field sales management, pharmaceutical and medical products marketing and sales, commercial strategy planning, and healthcare topics. He has extensive knowledge in B2B and B2C business, software and hardware product portfolios and offerings in the US and Germany. His passion for the impact technology can have on a large scale has been the red thread throughout his career. André holds doctorates from the University of Würzburg in medicine and the University of Freiburg in dental medicine.
André joined Sandoz in June 2018 from his role as CSO at Thermondo GmbH, an integrated energy company offering state-of-the-art energy efficiency services and applying digital process excellence and quality management. This year, The Financial Times named Thermondo #2 fastest growing company in Europe as well as one of the 100 most influential clean-tech companies in the world.
Before that, André was Vice President of Local Sales at Zocdoc, Inc. Zocdoc is an online service that identifies in-network neighborhood physicians, books appointments, shares patient reviews, provides appointment and check-up reminders, and automatically fills in paperwork. Zocdoc is free for patients and available across the United States.
Chihiro leads business development and manages relationship with partner venture capitals for Rx+ Business in Astellas. Rx+ is a concept of new healthcare solution created by combining innovative new technology in different field and Astellas capabilities developed in pharma business. In her role, Chihiro actively seeks partnership and investment opportunities in the growing field of Rx+ business, with high focus in digital health and medical device. Chihiro has 15 years of industry experiences in research and Business Development in addition to Rx+ business. She received an MSc from Waseda University and an MBA from Tsukuba University.
Dr. Gandhi is a Principal at Longwood Fund, where he creates and invests in science-based companies that develop novel solutions for major medical problems. Prior to Longwood, he was an attending hospitalist at the Massachusetts General Hospital, where he also trained as a resident physician in internal medicine. He previously held an investing role at Excel Venture Management, where he evaluated early-stage biopharmaceutical and healthcare IT investments, an operating role at Wellable, where he helped to build a mobile corporate wellness startup as its Chief Medical Officer, and consulting roles at McKinsey & Company and the TriZetto Corporation. He holds an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School, where he was a Baker Scholar, a D.Phil. in medical oncology from the University of Oxford where he was a Rhodes Scholar, and a B.S. with honors in biochemistry from Case Western Reserve University. He is the Secretary/Treasurer of the Suffolk District Medical Society, the professional medical society of Boston, and is a past trustee of the Massachusetts Medical Society and Boston Medical Library.
2018 Agenda
2019 Agenda To Be Announced This May
Click to download our full event agenda.
“DTx is a great event! There is a great mix of digital innovators and large companies which delivered high-quality content. I learn a lot and it’s great to see this community come together and have authentic interactions.”
Adam Kaufman, CEO, Canary Health
DTx East Venue 2019
Joseph B. Martin Conference Centre
At Harvard Medical School
The 2nd Annual Edition of DTx East is being held within the New Research Building at Harvard Medical School, The Joseph B. Martin Conference Center.
Located in the heart of Boston’s Longwood Medical Area, Harvard Medical School offers a new standard of excellence.
With beautifully designed warm wood interior, comfortable seating, excellent acoustics and visuals, plus generous networking space, a visit to this impressive venue will certainly be a memorable experience.
More details about the venue and nearby accommodation will be included in your welcome pack.
Registration
Sponsorship
The DTx series brings together the key decision makers in this rapidly growing industry. Our extensive networking and research enable us to develop a world-class speaker faculty, which in turn attracts a senior-executive audience.
We have a limited number of sponsor positions available for suitable organisations. If you want to be positioned at the heart of this sector, we would be happy to discuss the most suitable option for you.
With the launch of DTx East and the DTx hub, as well as the established DTx West meeting, this series is leading the way in providing the essential meeting place for digital therapeutic and digital medicine companies.
For an initial conversation please contact sam@greygreenmedia.com
Contact Us
